Atezolizumab

Atezolizumab is indicated for the treatment of patients with locally advanced or metastatic urothelial carcinoma (UC):

  • After prior chemotherapy, or
  • Who are considered cisplatin ineligibleand whose tumours have a PD-L1 expression ≥ 5%, or
  • Who are not eligible for any platinum-containing chemotherapy regardless of level of tumor PD-L1 expression.

Atezolizumab is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer NSCLC after prior chemotherapy.

There are no products to list in this category.

Continue